Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia

Am J Hematol. 2021 Feb 1;96(2):E50-E53. doi: 10.1002/ajh.26044. Epub 2020 Nov 21.

Authors

Guillermo Montalban-Bravo¹, Rashmi Kanagal-Shamanna², Veronica Guerra¹, Jorge Ramos-Perez¹, Danielle Hammond¹, Paul Shilpa³, Kiran Naqvi¹, Koji Sasaki¹, Elias Jabbour¹, Courtney DiNardo¹, Koichi Takahashi¹, Marina Konopleva¹, Naveen Pemmaraju¹, Tapan Kadia¹, Farhad Ravandi¹, Naval Daver¹, Gautam Borthakur¹, Zeev Estrov¹, Joseph D Khoury², Sanam Loghavi², Sherry Pierce¹, Carlos Bueso-Ramos², Keyur Patel², Hagop Kantarjian¹, Guillermo Garcia-Manero¹

Affiliations

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
² Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
³ Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

PMID: 33156969
DOI: 10.1002/ajh.26044

No abstract available

Keywords: chronic myelomonocytic leukemia; clinical outcomes; mutational dominance; olygomonocytic.

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Disease-Free Survival
Female
Humans
Leukemia, Myelomonocytic, Chronic / genetics*
Leukemia, Myelomonocytic, Chronic / mortality*
Male
Middle Aged
Mutation*
Neoplasm Proteins / genetics*
Survival Rate

Substances

Neoplasm Proteins

Grants and funding

CA016672/CA/NCI NIH HHS/United States